CORT Aug 2024 27.000 call
- Zacks
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
- GlobeNewswire
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpo
- Simply Wall St.
3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
As global markets experience fluctuations influenced by economic data and geopolitical tensions, investors are keenly watching the U.S. market for stable investment opportunities. High insider ownership in growth companies can be a strong signal of confidence in the company’s future, making such stocks potentially attractive in these uncertain times.
